会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Apparatus for stimulating components in, on, or near the pudendal nerve or its branches to achieve selective physiologic responses
    • 用于刺激阴部神经或其分支中,上或附近的组分以实现选择性生理反应的装置
    • US07571000B2
    • 2009-08-04
    • US11402036
    • 2006-04-11
    • Joseph W. Boggs, IIBrian J. WenzelKenneth J. GustafsonWarren M. Grill
    • Joseph W. Boggs, IIBrian J. WenzelKenneth J. GustafsonWarren M. Grill
    • A61N1/36
    • A61N1/36196A61N1/36007A61N1/37247
    • Apparatus for control of physiological functions, including physiological functions of the urinary tract, using at least one electrode sized and configured to be located on, in, or near a targeted component of the pudendal nerve, and/or its branch(es), and/or its spinal root(s). The apparatus includes a controller coupled to the electrode to apply an electrical signal having an amplitude to the electrode at a selected frequency to stimulate the targeted component. The controller operates in a first mode to apply a first frequency or range of frequencies without substantially changing the amplitude for achieving a first physiologic response (e.g., controlling urinary continence) and the controller operates in a second mode to apply a second frequency or range of frequencies, different than the first frequency, for achieving a second physiologic response different than the first physiologic response (e.g., controlling micturition).
    • 用于控制生理功能的装置,包括尿道的生理功能,使用至少一个尺寸和构造为位于阴部神经和/或其分支的目标组分中,附近或附近的电极和/或其分支,以及 /或其脊髓根部。 该装置包括耦合到该电极的控制器,以一选定频率将具有振幅的电信号施加到该电极上以刺激该目标部件。 控制器以第一模式操作以施加第一频率或频率范围,而基本上不改变振幅以实现第一生理响应(例如,控制尿路),并且控制器以第二模式操作以施加第二频率或范围 频率,不同于第一频率,用于实现与第一生理反应不同的第二生理反应(例如,控制排尿)。
    • 5. 发明授权
    • Systems and methods for activating and controlling impedance-based detection systems of implantable medical devices
    • 用于激活和控制可植入医疗设备的基于阻抗的检测系统的系统和方法
    • US08295918B2
    • 2012-10-23
    • US13035773
    • 2011-02-25
    • Stuart RosenbergCecilia Q. XiYelena NabutovskyBrian J. WenzelJong GillWilliam Hsu
    • Stuart RosenbergCecilia Q. XiYelena NabutovskyBrian J. WenzelJong GillWilliam Hsu
    • A61B5/04
    • A61N1/3627A61N1/3702A61N1/372
    • Techniques are provided for use with implantable medical devices for addressing encapsulation effects, particularly in the detection of cardiac decompensation events such as heart failure (HF) or cardiogenic pulmonary edema (PE.) In one example, during an acute interval following device implant, cardiac decompensation is detected using heart rate variability (HRV), ventricular evoked response (ER) or various other non-impedance-based parameters that are insensitive to component encapsulation effects. During the subsequent chronic interval, decompensation is detected using intracardiac or transthoracic impedance signals. In another example, the degree of maturation of encapsulation of implanted components is assessed using impedance frequency-response measurements or based on the frequency bandwidth of heart sounds or other physiological signals. In this manner, impedance-based HF/PE detection systems can be activated as soon as component encapsulation has matured, without necessarily waiting until completion of a preset post-implant maturation interval, often set to forty-five days or more.
    • 提供技术用于可植入医疗装置,用于解决封装效应,特别是在心脏代偿失调事件如心力衰竭(HF)或心源性肺水肿(PE)的检测中。在一个实例中,在装置植入后的急性期间,心脏 使用心率变异性(HRV),心室诱发反应(ER)或对组件封装效应不敏感的各种其他基于非阻抗的参数来检测代偿失调。 在随后的慢性间隔期间,使用心内或经胸阻抗信号检测代偿失调。 在另一示例中,使用阻抗频率响应测量值或基于心脏声音或其他生理信号的频率带宽来评估植入部件的封装的成熟程度。 以这种方式,一旦组件封装已经成熟,就可以激活基于阻抗的HF / PE检测系统,而不必等待直到完成植入后成熟间隔的预设,通常设置为四十五天或更长时间。
    • 7. 发明授权
    • Method and implantable system for blood-glucose concentration monitoring
    • 血糖浓度监测方法及植入式系统
    • US08092386B1
    • 2012-01-10
    • US11615591
    • 2006-12-22
    • Brian J. WenzelTaraneh Ghaffari Farazi
    • Brian J. WenzelTaraneh Ghaffari Farazi
    • A61B5/00
    • A61B5/14532A61B5/0031A61B5/01A61B5/02055A61B5/021A61B5/024A61B5/14551A61B5/1459A61B5/4839A61M5/14276A61N1/36557
    • In an implantable medical device for monitoring blood-glucose concentration in the blood, metabolic oxygen consumption is derived by measuring physiological metrics related to mixed venous oxygen concentration. Blood-glucose concentration is determined using correlations of blood-glucose concentration with measures of metabolic oxygen consumption including oxymetric, temperature, and electrocardiographic data. Additional physiological sensor measurements may be used to enhance the accuracy of the analysis of blood-glucose concentration. By using a combination of oxymetric and other physiological metrics, blood-glucose concentration can be reliably calculated over a wide range. The device compares the blood-glucose concentration with upper and lower acceptable bounds and generates appropriate warning signals if the concentration falls outside the bounds. The device may also control a therapeutic device to maintain blood-glucose concentration within an acceptable range. A calibration technique determines patient-specific parameters for use in the calculation of blood-glucose concentration.
    • 在用于监测血液中血糖浓度的可植入医疗装置中,通过测量与混合静脉血浓度相关的生理指标,可得出代谢氧消耗。 使用血糖浓度与代谢氧消耗量的相关性(包括氧测量,温度和心电图数据)来确定血糖浓度。 可以使用额外的生理传感器测量来提高血糖浓度分析的准确性。 通过使用氧化度和其他生理指标的组合,可以在宽范围内可靠地计算血糖浓度。 该装置将血糖浓度与上限和下限可接受的范围进行比较,如果浓度超出界限,则产生适当的警告信号。 该装置还可以控制治疗装置以将血糖浓度维持在可接受的范围内。 校准技术确定用于计算血糖浓度的患者特异性参数。